Veritable’s Aerie Pharmaceuticals AERI Stock Holding History

Veritable’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,968	Closed	-$136K	–	936
2021 Q3	$136K	Buy	+11,968	New	+$175K	﹤0.01%	859

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Veritable's AERI Position: Q4 2021 in Review

Veritable sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 11,968 shares — an estimated $136K sold.

Veritable first reported a position in AERI in Q3 2021 and held it in 1 quarter. The position peaked at $136K in Q3 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

Veritable reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Veritable sold 11,968 Aerie Pharmaceuticals shares in Q4 2021, an estimated $136K.
Veritable first reported a position in Aerie Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Veritable's Aerie Pharmaceuticals position peaked at $136K in Q3 2021.
129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on Veritable's 13F filing for Q4 2021, filed 14 Feb 2022.